PURPOSE: To determine the frequency and distribution of parenchymal changes on mammography before and after hormone replacement therapy. MATERIALS AND METHODS: Mammograms of 100 postmenopausal women who underwent hormone replacement therapy without breast disease were evaluated. Mammograms obtained annually after hormone replacement were analysed and compared with that of pretreatment. In addition, mammograms of control group and treatment group were compared. RESULTS: An increase in density of breast parenchyma was seen on the mammogram of 20 women(20%) receiving therapy. The mammograms from the control group showed no change. Mammographic changes were detected at first year in 13 women, 2nd year in 4 women, 3rd year in 2 women, and 4th year in 1 woman (average,19 months). CONCLUSION: We conclude that increase in mammographic density following postmenopausal hormone replacement therapy is not uncommon(20%).
Breast Diseases ; Breast* ; Estrogen Replacement Therapy* ; Female ; Hormone Replacement Therapy ; Humans ; Mammography*

OBJECTIVE: Our purpose was to determine whether the bone resorption rate is evaluated by Deoxypyridinoline(Dpd) i urine, and to evaluate the clinical utility of Dpd to monitor the hormone replacement therapy effect in postmenopausal women. STUDY DESIGN: We divided the patients into three groups, the control group was the women who were postmenopausal health state, and the experimental groups were the postmenopausal hormone replacement therapy group and the podtmenopausal nontherapy group. Urinary Dpd and serum FSH, Osteocalcin was measured in the both groups. RESULTS: The urinary Dpd and serum osteocalcin were significantly increase in postmenopausal group(6.63+/-3.09 pmol/nmol creatinine; 10.54+/-3.77 ng/ml) compared to premenopausal group(4.15+/-1.32 pmol/nmol creatinine; 7.85+/-2.17 ng/ml). The urinary Dpd and Serum osteocalcin were significantly decreased in the postmenopausal HRT group(3.31+/-1.79 pmol/nmol creatinine; 8.31+/-3.13 ng/ml) compared to the postmenopausal nontherapy group (6.63+/-3.09 pmol/nmol creatinine; 10.54+/-3.77 ng/ml). In postmenopausal nontherapy group, there was no correlation between urinary Dpd and serum osteocalcin. But these makers were good correlated in postmenopausal HRT group. CONCLUSIONS: It is concluded that the assay of urinary Dpd is useful for the resorption marker of postmenopausal osteoporosis and it should be useful for the monitoring of hormone replacement therapy effect in postmenopausal women. Furthermore, urinary Dpd may be an important indicator to determine when to resume the therapy during cessation of HRT.
Bone Resorption ; Creatinine ; Estrogen Replacement Therapy ; Female ; Hormone Replacement Therapy* ; Humans ; Osteocalcin ; Osteoporosis, Postmenopausal

OBJECTIVE: The aim of the study is to assess the effects of treatment with an extract from Cimicifuga racemosa for 1 year in postmenopausal women with symptoms. METHODS: In a randomised, open-label, group-comparative study, the change on the Kupperman menopausal index, serum FSH and E2 level, bone densitometry (BMD), and mammographic density by an extract from Cimicifuga racemosa (GYNO-Qx ) (N=40) were compared with an conjugated equine estrogen combined with medroxyprogesterone acetate (CEE/MPA) (N=36) during 12 months in menopausal women. RESULTS: There were no statistical differences in the change of Kupperman index, serum FSH and E2 level, and mammographic density between two groups after 12 months, except the effect of BMD that the CEE/MPA group (+6.6%) was significantly increased as compared to the extract from Cimicifuga racemosa (+1.1%) baseline. CONCLUSION: This study suggests that an extract of Cimicifuga racemosa is a safe, effective alternative to estrogen replacement therapy for patients in whom hormone replacement therapy is either refused or contraindicated.
Cimicifuga* ; Densitometry ; Estrogen Replacement Therapy ; Estrogens ; Female ; Hormone Replacement Therapy ; Humans ; Medroxyprogesterone Acetate ; Menopause

A study in 51 healthy postmenopausal women was performed to assess the effect of estrogen replacement therapy continuously combined with progesterone for 6 months on bone mineral density and lipid metabolism.Seventeen hysterectomized women were treated with conjugated estrogen(0.625mg/D), 33 nonhysterectomized women with conjugated estrogen(0.625mg/D) and medroxyprogesterone(2.5mg/D), and 1500mg/day calcium supplementation was given to all patients.After 6 month-treatment, serum total cholesterol and LDL-cholesterol levels were reduced significantly (p<0.01) between the two groups. But lumber BMD and other lipid profiles were not changed significantly between the two groups. Our data suggest that continuously applied progesterone in combined hormone replacement therapy dose not annihilate the beneficial effects on bone mineral density and lipid metabolism induced by estrogen.
Bone Density ; Calcium ; Cholesterol ; Estrogen Replacement Therapy ; Estrogens ; Female ; Hormone Replacement Therapy ; Humans ; Lipid Metabolism ; Progesterone

BACKGROUND: Many reports have shown that hormone replacement therapy(HRT) in postmenopausal women decreases lipoprotein(a)[Lp(a)]. However these had small numbers of subjects, short duration of therapy, or comparisons of only a few regimens. The influences of progesterone on Lp(a) and lipids, administered with estrogen, are controversial. METHODS: Five hundred and fifty-one postmenopausal women were divided into 4 groups : group A ; 0.625mg conjugated equine estrogen(CEE)(m=140), group B ; 0.625mg CEE plus 5mg medroxyprogesterone acetate(MPA)(m=97), group C ; 0.625mg CEE plus 10mg MPA(n=109), and group D ; 2mg estradiol valerate(E2) plus 0.5mg norgestrel(N)(n=134) and group E ; control(n=71). Lp(a) and lipids levels were measured before and 12 months after HRT. RESULTS: Estrogen replacement therapy(ERT) for 12 months lowered Lp(a) level by 37.1%. The addition of progesterone attenuated the Lp(a)-lowering effect of estrogen and decreased by 27.7%, 29.6%, and 30.3% in groups B(p<0.05), C(p<0.05), and D(p<0.0001) respectively. High density lipoprotein cholesterol(HDL-C) was increased markedly in group A(16.5%), increased moderately in groups B(10.8%) and C(11.3%), and not changed in group D. Low density lipoprotein cholesterol was decreased by 10.9%, 13.7%, 11.3%, and 17.6% in groups A, B, C, and D respectively. CONCLUSIONS: Reduction of Lp(a) with estrogen replacement therapy may be one of mechanisms for cardioprotective effect in postmenopausal women. The combined therapy of estrogen and progesterone may reveal different effects on heart due to adverse actions of progesterone on Lp(a) and HDL-C. The variations in the androgenic potency of progesterone may explaine inconsistent results on HDL-C in previous studies.
Cholesterol, LDL ; Estradiol ; Estrogen Replacement Therapy ; Estrogens ; Female ; Heart ; Hormone Replacement Therapy* ; Humans ; Lipoprotein(a)* ; Lipoproteins ; Medroxyprogesterone ; Progesterone*

OBJECTIVE: To investigate the incidence of non-responder to hormone replacement therapy (HRT) and to evaluate the bone response to HRT according to basal bone mineral density(BMD) in postmenopausal women. METHODS: A total of 211 postmenopausal women received either continuous combined estrogen-progestogen replacement (n=112) or estrogen replacement (n=99) for 1 years. BMD at the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry (DEXA) before and 1 year after HRT. RESULTS: The incidence of non-responder (women with > 3% bone loss per year) to HRT was 9.2% in the lumbar spine, and 23.8% in femoral neck. Estrogen replacement group had a higher incidence of non-responder than combined replacement group. Non-responder group had a higher basal BMD at the lumbar spine than responder group, and showed bone loss rate of 7.6% per year. After 1 year of HRT, postmenopausal women with osteoporosis showed a higher rate of increase in BMD at the lumbar sine and femoral neck than women with normal BMD or osteopenia. CONCLUSION: The non-responders to HRT have a higher basal lumbar BMD, compared with responders. The higher basal BMD at the lumbar spine is, the less bone conservation effect of HRT is.
Absorptiometry, Photon ; Bone Density* ; Bone Diseases, Metabolic ; Estrogen Replacement Therapy ; Female ; Femur Neck ; Hormone Replacement Therapy* ; Humans ; Incidence ; Osteoporosis ; Spine

Newly developed genetic techniques can reveal mosaicism in individuals diagnosed with monosomy X. Noninvasive prenatal diagnosis using maternal blood can detect most fetuses with X chromosome abnormalities. Low-dose and ultralow-dose estrogen replacement therapy can achieve a more physiological endocrine milieu. However, many complicated and controversial issues with such treatment remain. Therefore, lifetime observation, long-term studies of health problems, and optimal therapeutic plans are needed for women with Turner syndrome. In this review, we discuss several diagnostic trials using recently developed genetic techniques and studies of physiological hormone replacement treatment over the last 5 years.
Diagnosis ; Estrogen Replacement Therapy ; Female ; Fetus ; Genetic Techniques ; Hormone Replacement Therapy ; Humans ; Mosaicism ; Prenatal Diagnosis ; Turner Syndrome* ; X Chromosome

OBJECTIVE: The purpose of this study was to study the clinical efficacy of Levonorgestrel-releasing intrauterine system (Mirena(R)) for patients who have abnormal uterine bleeding before menopause or sustaining vaginal spotting during postmenopaual hormone replacement therapy. METHODS: Between June, 2001 and June, 2003, forty six premenopausal women with abnormal uterine bleeding such as menorrhagia and intermenstrual bleeding who did not prefer surgical treatment (Group 1) and twenty four postmenopausal patients with vaginal spotting (Group 2) were included in this study. The various parameters such as uterine bleeding, dysmenorrhea, volume changes of myoma or adenomyosis, and endometrial thickness were evaluated by transvaginal ultrasound examination before and after Levonorgestrel- releasing intrauterine system usage. RESULTS: A significant reduction in abnormal bleeding (26.3 vs 11.0) (p<0.0001) and dysmenorrhea (11.6 vs 6.1) (p<0.0001) were noticed. However, there was no significant change in volume of uterine myoma (40.0 vs 11.3) (p=0.282) and adenomyosis (103.0 vs 95.83) (p=0.266) before and after Mirena(R) insertion in Group 1. Vaginal spotting during hormone replacement therapy disappeared completely in 18/24. Also there was a significant reduction in endometrial thickness (6.3 vs 4.9) (p<0.0001) after Mirena(R) insertion in both group 1 and group 2. CONCLUSION: Levonorgestrel-releasing intrauterine system insertion was acceptable and convenient therapeutic modality for abnormal uterine bleeding of premenopausal abnormal uterine bleeding and vaginal spotting during the postmenopausal hormone replacement therapy.
Adenomyosis ; Dysmenorrhea ; Estrogen Replacement Therapy ; Female ; Hemorrhage ; Hormone Replacement Therapy ; Humans ; Leiomyoma ; Menopause ; Menorrhagia ; Metrorrhagia ; Myoma ; Ultrasonography ; Uterine Hemorrhage*

No abstract available.
Hormone Replacement Therapy*

No abstract available.
Hormone Replacement Therapy*